Targeting CD22 in B-cell malignancies: current status and clinical outlook.
about
Targeted Therapies in Adult B-Cell MalignanciesNew Therapeutic Strategies in Acute Lymphocytic Leukemia.A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Siglec-mediated regulation of immune cell function in disease.Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor CellsIntravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Novel therapeutic options for relapsed hairy cell leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.Emerging immunotherapy in pediatric lymphoma.Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemiaTwo Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.New Human CD22/Siglec-2 Ligands with a Triazole Glycoside.High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas.Molecular basis of human CD22 function and therapeutic targeting.Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.Cell-based glycan arrays for probing glycan-glycan binding protein interactions.Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress.CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
P2860
Q26783195-5DBE64C8-0965-4BA8-80C8-9358F84F91DEQ30252776-81C9AC68-90B7-4B6F-BAF8-8C9D8904FECEQ33758660-55DF029E-6AC4-4C54-80FE-CAECF79C219EQ34314957-B86FCA85-0295-4F9B-B9E2-95CAB905417BQ34416178-7E4CEBD3-18EC-483A-B9E7-41FE726CBCFCQ35987358-9339FDE7-415A-4250-BA09-D2401C02D013Q36269852-264DB51B-2901-45D5-AE6E-40F3220BA95BQ38133405-69CE2470-7D32-4437-A914-78013C5194F1Q38308974-23182457-8679-4955-B998-FFE4CA9E607FQ38543771-7B5EB139-7478-44BE-BBC0-8F3CE60313C9Q38598881-54A45BBC-BFB7-43D9-A112-4C7B50E8BC9DQ38652326-5B8C3B07-0839-491D-AE00-FAFD5D5823AFQ38701163-1AFB4E94-488A-4B12-879B-2F8E2246E5AFQ38701886-C84EEC5D-F041-44C9-B190-072BC6C1D137Q38709008-24E79756-1502-48DF-A634-3755F158D1BFQ38837764-A11106A8-4207-40B3-8901-7A7224ADD58FQ40415354-50536E76-03A2-4ADB-9F70-263A0EFDA0BBQ42286136-56FFDB8B-8F5C-42E6-95FC-362A949383B9Q51031788-BE949344-FC6B-4B04-AA67-A4CD9B8B8BE1Q51730575-E6D643AA-13C6-42AC-9749-1E2CA3CE1363Q53814000-B555CAD7-11F7-4B0F-83C5-D885FC52E236Q57490095-F2CF167A-933C-4737-9053-DA29C5C9116C
P2860
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
@en
type
label
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
@en
prefLabel
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
@en
P2093
P2860
P1433
P1476
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
@en
P2093
Joseph M Tuscano
Loretta Sullivan-Chang
Robert T O'Donnell
P2860
P2888
P304
P356
10.1007/S40259-013-0016-7
P577
2013-08-01T00:00:00Z